Vaccines and Global Health: The Week in Review
19 March 2022 :: Issue 649
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to contribute and thank you in advance for your support.

Contents  [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Emergencies
:: Organization Announcements
:: Journal Watch
The overall situation continues to deteriorate across Ukraine. To date, over 18 million people have been affected by the conflict. According to the latest government data compiled by the United Nations High Commissioner for Refugees (UNHCR), over three million refugees have now left Ukraine for surrounding countries, with over 60% of them in Poland. It is estimated that this number could rise to four million by July 2022.

[Excerpt]

2.2.2 Priority public health concerns

iv. Risk of emergence and spread of infectious diseases

Ongoing epidemics

A total of 35,396 new cases of COVID-19 and 556 new deaths were reported in Ukraine from 10 to 16 March. However, the seven-day average number of polymerase chain reaction tests decreased from 42,460 to 3913 from 23 February to 14 March, and the seven-day average number of antigen rapid diagnostic tests dropped from 51,484 to 3038. Therefore, the number of COVID-19 cases is likely to be underreported.

Epidemic risk

Poor ventilation and overcrowding increase the risk of spread of respiratory infections, including COVID-19. Lack of access to safe water and sanitation heightens the risk of the emergence of water-borne diseases. Of note, an outbreak of cholera was identified in Ukraine in 2011 in the Mariupol region, an area currently experiencing an escalation in conflict. A single case of cholera was also detected in the Zaporizhzhia oblast in 2016, highlighting the possibility of cholera cases occurring in parts of the country.

Suboptimal vaccination coverage of routine and childhood immunizations, including measles and poliomyelitis (polio), increases the risk of re-emergence and transmission of vaccine-preventable diseases.

With the arrival of spring and rising temperatures, disrupted access to safe water, sanitation and hygiene, and damage to homes may increase the risk of vector-borne diseases such as West Nile fever and tick-borne encephalitis.

Lack of access to barrier contraception and increased risk of sexual and gender-based violence increases the risk of sexually transmitted infections...
Polio Vaccination - Africa

**More than 80 million doses to be administered to southern African children targeted in mass polio vaccination drives**
18 March 2022

Brazzaville/Lilongwe – Malawi will on Sunday launch the first round of vaccination campaigns against wild poliovirus type 1. **More than 80 million doses will be administered to more than 23 million children under 5 years in the four-round vaccination drive in five southern African countries after Malawi declared an outbreak on 17 February—the first such case in the country in 30 years, and the first in Africa since the region was certified free of indigenous wild poliovirus in 2020.**

The first phase of the campaigns targets 9.4 million children in **Malawi, Mozambique, Tanzania and Zambia.** Three subsequent rounds—in which **Zimbabwe** will also take part—are set for April, June and July and aim to reach over 23 million children with more than 80 million doses of the bivalent Oral Polio Vaccine recommended by World Health Organization (WHO) for wild poliovirus (type 1).

Mass vaccinations, or supplementary vaccinations, aim to interrupt the circulation of poliovirus by immunizing every child under 5 years with oral polio vaccine regardless of previous immunization status. The objective is to reach children who are either not immunized, or only partially protected, and to boost immunity in those who have been immunized. Supplementary immunization is intended to complement—not replace—routine immunization...

...The African region was declared and certified as free of indigenous wild polio in August 2020 after eliminating all forms of wild poliovirus. The region’s certification as wild polio-free remains unchanged. Laboratory analysis linked the strain detected in Malawi to the one circulating in Pakistan’s Sindh Province in 2019...

...In preparation for the vaccination drives, trained surge teams of national officers have been deployed at district level to facilitate the campaign and ensure that all eligible children are vaccinated. Maintenance and repair of cold chain facilities are also ongoing...

COVID Vaccination - Africa

**Africa’s COVID-19 vaccine uptake increases by 15%**
17 March 2022

Brazzaville – Africa’s COVID-19 vaccine uptake rose by 15% between January and February as several countries embarked on mass vaccination drives to expand coverage and protect populations against the adverse health impacts of the virus.

Around 62 million doses were administered across the continent in February up from 54 million in January. **The uptick was driven mainly by vaccination campaigns in populous countries**
including Democratic Republic of the Congo, Ethiopia, Kenya, and Nigeria. To boost the COVID-19 vaccine uptake in Africa, World Health Organization (WHO), UNICEF, Gavi, the Vaccine Alliance, and partners are supporting mass vaccination drives in at least 10 priority countries to reach 100 million people by the end of April 2022...

...“The vaccination drives have ignited a positive momentum against the pandemic in Africa. With every additional person vaccinated, the weaker the power of COVID-19 over our lives becomes,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “While this progress is welcome, the pace of vaccination across the continent needs to increase nine-fold if we are to reach our target of vaccinating 70% of the population by June 2022.”

To date, the continent has fully vaccinated just 15% of the adult population. Of the 714 million doses received so far, 435 million or 61% has been administered. Fifteen countries are yet to reach 10% of their population fully vaccinated. Twenty-one African countries have fully vaccinated between 10% and 19% of their populations. Five countries have fully vaccinated between 40% and 69% of their populations. Only Mauritius and Seychelles have surpassed 70% vaccination coverage...

As Africa strives to step up vaccine uptake, it is witnessing a sustained decline in COVID-19 cases. Reported cases have fallen for nine straight weeks since the peak of the fourth pandemic wave in early January. The continent reported a 10% decline in cases in the week ending on 13 March compared with the week before. Deaths declined by 37% over the same period...

::::::

::::::

TRIPS IP Waiver - WTO Action

Wall Street Journal

World

Countries Try to Win Support for Deal to Waive Patent Protections on Covid-19 Vaccines

Compromise reached by U.S., EU, South Africa and India needs approval from World Trade Organization membership

By Saeed Shah

March 17, 2022

After 18 months of fierce debate, a group of countries, including the U.S., has reached an agreement to waive patent protections on Covid-19 vaccines. Now they are racing to get other countries to support the deal at the World Trade Organization, officials involved in the discussions said.

The U.S. and the European Union have reached a compromise with South Africa and India that would allow developing countries to manufacture Covid-19 vaccines without the permission of the holder of the intellectual-property rights. It also would set a precedent for future pandemics...

...The U.K. and Switzerland, which have major pharmaceutical industries and opposed the waiver, weren’t part of the talks on the agreement. They complained of a lack of transparency around negotiations over the deal in a WTO meeting of all members on March 9, trade officials said...

...“The difficult and protracted process has resulted in a compromise outcome,” said the U.S. Trade Representative. “While no agreement on text has been reached and we are in the process of consulting
on the outcome, the U.S. will continue to engage with WTO Members as part of the Biden-Harris Administration’s comprehensive effort to get as many safe and effective vaccines to as many people as fast as possible.”…

::::::

**Director-General Okonjo-Iweala hails breakthrough on TRIPS COVID-19 solution**

16 March 2022

World Trade Organization Director-General Ngozi Okonjo-Iweala today warmly welcomed the breakthrough among four WTO Members on a waiver of the Trade Related Intellectual Property agreement for the production of vaccines against the COVID-19 pandemic.

“This is a major step forward and this compromise is the result of many long and difficult hours of negotiations. But we are not there yet. We have more work to do to ensure that we have the support of the entire WTO Membership,” the Director-General said.

While the agreement between the European Union, India, South Africa and the United States is an essential element to any final deal, she cautioned that not all the details of the compromise have been ironed out and that internal domestic consultations within the four members are still ongoing. Moreover, she stressed that work must commence immediately to broaden the discussions to include all 164 members of the WTO.

“In the WTO we decide by consensus, and this has not yet been achieved. My team and I have been working hard for the past three months and we are ready to roll up our sleeves again to work together with the TRIPS Council Chair Ambassador Lansana Gberie (Sierra Leone) to bring about a full agreement as quickly as possible. We are grateful to the four Members for the difficult work they have undertaken so far,” said Dr. Okonjo-Iweala.

::::::

**IFPMA statement on TRIPS discussion document**

16 March 2022  [Text bolding from original]

Following reports on the status of informal discussions led by the WTO Secretariat with the European Union (EU), India, South Africa, and the USA, on 16 March 2022, biopharmaceutical companies reaffirm their position that weakening patents now when it is widely acknowledged that there are no longer supply constraints of COVID-19 vaccines, sends the wrong signal.

2022 kicked off with COVID-19 vaccine production from both developing and developed country manufacturers reaching 12 billion within a year of the first vaccine being authorized. Today industry is able to produce over a billion vaccine each month. COVAX is now fully meeting its commitments. Since the beginning of 2022, there has been broad consensus that the challenge now is how to get the vaccines into the arms of people who need them, rather than vaccine supply. When the IP TRIPS Waiver was first proposed in 2020, it was to the wrong solution to the problem of scaling up manufacturing of potential COVID-19 vaccines which at the time had not yet even been authorized. Now the problem of supply has been addressed thanks to unprecedented collaboration involving companies from industrialized and developing countries, the TRIPS Waiver is not only the wrong solution, it is also an outdated proposal, that has been overtaken by events.
Weakening intellectual property (IP) will do nothing to help the scaling up of vaccine manufacturing. There is a broad consensus among experts that waiving patents would not add a single additional vaccine dose, because technology transfer goes far beyond the patent, is built on trust, know-how sharing and voluntary licensing. This is exactly what manufacturers have done on an unprecedented scale. As of now, there are 371 collaborations on vaccines manufacturing and 155 for therapeutics and, in addition, the multiple announcements of partnerships to improve geographical diversity of vaccine production, are proof in themselves that the proposed IP TRIPS waiver is unnecessary and irrelevant, at worst sends the wrong signal at the wrong time.

The IP TRIPS Waiver proposals should be recognized for what they are – political posturing that are at best a distraction, at worse creating uncertainty that can undermine innovation’s ability to respond to the current and future response to pandemics. The current proposals should be shelved; and the focus should be directed, to admittedly more difficult actions that will change lives for the better: supporting country readiness, contributing to equitable distribution, and driving innovation (Ref Three priorities to urgently increase access to COVID-19 vaccines).

OXFAM - Media reaction in response to reports of a compromise on the vaccines TRIPS waiver
16 March 2022  OXFAM
In response to reports of a potential compromise agreed by the EU, South Africa, India and the US for a waiver of intellectual property rules for COVID vaccines, Max Lawson, Head of Inequality Policy for Oxfam and co-chair of the People’s Vaccine Alliance, said:

“After almost 18 months of stalling and millions of deaths, the EU has climbed down and finally admitted that intellectual property rules and pharmaceutical monopolies are a barrier to vaccinating the world. This is a tribute to millions of campaigners across the world who have demanded a Peoples’ Vaccine, but this leaked proposal is not the comprehensive TRIPS waiver demanded by over 100 governments. Unless it is significantly improved it will not do enough to bring an end to vaccine apartheid and ensure access for all.

“As it stands, this proposal seems to do little to address patents beyond the existing flexibilities in the TRIPS agreement. It ignores other intellectual property barriers like trade secrets which stand in the way of vaccine manufacturers. And by focusing only on vaccines and kicking the issue of COVID-19 treatments into the long grass, it will leave life-saving treatments out of reach for millions.

“In a crisis, half measures are not acceptable. Every barrier to accessing these crucial vaccines and treatments must be cleared away. We urge member states to return to the negotiating table and come back with a comprehensive waiver that will work to cut short this pandemic and guarantee everyone is protected.”

Notes to editors
The People’s Vaccine Alliance is a coalition of nearly 100 organizations and networks, supported by Nobel Laureates, health experts, economists, Heads of States, faith leaders and activists, working together for a People’s Vaccine, available free of charge to everyone, everywhere.
**Weekly Epidemiological and Operational updates**

*Last update: 18 Mar 2022*

**Confirmed cases:** 464,809,377

**Confirmed deaths:** 6,062,536

**Vaccine doses administered:** 10,925,055,390

---

**17 March 2022**

*Speech*

**WHO Director-General's opening remarks at the Member State Information Session on COVID-19 - 17 March 2022**

---

**16 March 2022**

*Speech*

**WHO Director-General's opening remarks at the WHO press conference – 16 March 2022**

---

**Weekly epidemiological update on COVID-19 - 15 March 2022**

*Overview*

After a consistent decrease in the number of new COVID-19 cases reported globally on a weekly basis since the end of January 2022, during the week of 7 through 13 March 2022, the number of new weekly cases has increased by 8% as compared to the previous week. Across the six WHO regions, over 11 million new cases and just over 43,000 new deaths were reported. As of 13 March 2022, over 455 million confirmed cases and over 6 million deaths have been reported globally.

At the regional level, the Western Pacific Region, the African Region and the European Region reported an increase in new weekly cases of 29%, 12% and 2%, respectively, as compared with the previous week; while a decrease has been reported by the Eastern Mediterranean Region (-24%), the South-East Asia Region (-21%) and the Region of the Americas (-20%).

The number of new weekly deaths decreased globally by 17%. At the regional level, the Western Pacific Region reported an increase in new weekly deaths (+12%), while decreases were reported by the Eastern Mediterranean Region (-49%), the African Region (-41%), Europe Region (-23%), the Region of the Americas and South-East Asia Region (both -15%).

In this edition we provide:

- Updates on the new WHO Designation of SARS-CoV-2 Variants
- Updates on the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), including the spread and prevalence of the Omicron variant.
- Special Focus: Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance
**Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 March 2022**

[Full scale view available at title link above]

[Updated on 02 March 2022]

---

**COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements**

[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

**AstraZeneca**

*Press Releases* - No new digest announcements identified

**Bharat Biotech**

*Press Releases*

Mar 16: **Bharat Biotech and Biofabri partner to develop, manufacture and distribute a novel TB vaccine, MTBVAC**

**BioCubaFarma** – Cuba

*Últimas Noticias* - Website not leading at inquiry

**Biontech**

*Press Releases*

**Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults**

15 March 2022

**CanSinoBIO**
Clover Biopharmaceuticals - China
News
Mar 17, 2022
**Clover’s COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster**

--100% efficacy maintained against severe COVID-19 and 95% efficacy against hospitalization at five months after second dose of SCB-2019 (CpG 1018/Alum)--
--Significant neutralizing antibodies against Omicron induced by SCB-2019 (CpG 1018/Alum) third dose in both homologous and heterologous booster settings--

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia below.

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Moderna
Press Releases
March 17, 2022
**Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.**

March 17, 2022
**Health Canada Authorizes Moderna’s COVID-19 Vaccine in Children (6-11 Years)**

March 16, 2022
**Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna’s COVID-19 Booster Vaccine**

Novavax
Press Releases - No new digest announcements identified

Pfizer
Recent Press Releases
03.15.2022
**Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults**

Sanofi Pasteur
Press Releases - No new digest announcements identified
Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases
Chile Research: CoronaVac® is safe and likely to confer protection against infection caused by SARS-CoV-2 variants in participants aged 3-17 years old
2022/03/16

Chile Study: The World's First Real-World Study on the Effectiveness of CoronaVac Among Children 3 to 5 Years Old During Omicron Outbreak
2022/03/16

Latest Real-World Data Show Two-shots of CoronaVac® Provides 74.5% Protection Against COVID-19 For Children and Adolescents
2022/03/16

Vector State Research Centre of Viralogy and Biotechnology
Home - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

GSK
Press releases for media - No new digest announcements identified

Merck
News releases - No new digest announcements identified

Novartis
News - No new digest announcements identified

SK Biosciences
Press releases - No new digest announcements identified

Valneva
Press Releases - No new digest announcements identified
UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 19 Mar 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]

- 35 vaccines approved for use by at least one national regulatory authority
- 10 vaccines in WHO’s Emergency Use Listing
- 17.6bn doses secured globally
- $2 - $40 reported vaccine price range per dose
- 2.8bn doses COVAX has secured from funded agreements and confirmed donations
- 1.38bn doses shipped through COVAX to 144 countries

COVID-19 Global Targets and Progress Tracker - IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)
Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

See also visualization on Vaccine Access and Vaccine Affordability

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/
Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID-19 Data Explorer: Global Humanitarian Operations

**COVID-19 Vaccine Roll-out**

**19 Mar 2022** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 465M total confirmed cases; 6.1M total confirmed deaths

Global vaccines administered: 11.0B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 260M

Other Delivered (Number of Doses): 260M

Total Delivered (Number of Doses): 520M

Total Administered (Number of Doses): 350M

---

**Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]**

https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.


---

**Our World in Data**
- 64% of the world population has received at least one dose of a COVID-19 vaccine.  
  10.99 billion doses have been administered globally, and 17.03 million are now administered each day. 
  Only 14.4% of people in low-income countries have received at least one dose.
U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS
News
No new digest content identified.

BARDA – U.S. Department of HHS  [to 19 Mar 2022]
https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx
News
No new digest content identified.

FDA
Press Announcements
No new digest content identified.

Vaccines and Related Biological Products Advisory Committee- FDA
Calendar
No calendar announcements identified.

White House [U.S.]  [to 19 Mar 2022]
Briefing Room – Selected Major COVID Announcements
FACT SHEET: Biden Administration Launches Effort to Improve Ventilation and Reduce the Spread of COVID-19 in Buildings
March 17, 2022 • Statements and Releases

Statement by President Joe Biden on the White House COVID-19 Response Coordinator
March 17, 2022 • Statements and Releases
  ...To lead this effort, I am excited to name Dr. Ashish Jha as the new White House COVID-19 Response Coordinator. Dr. Jha is one of the leading public health experts in America, and a well known figure to many Americans from his wise and calming public presence. And as we enter a new moment in the pandemic – executing on my National COVID-19 Preparedness Plan and managing the ongoing risks from COVID – Dr. Jha is the perfect person for the job.
  I appreciate both Jeff and Dr. Jha for working closely to ensure a smooth transition, and I look forward to continued progress in the months ahead.

FACT SHEET: Consequences of Lack of Funding for Efforts to Combat COVID-19 if Congress Does Not Act
March 15, 2022 • Statements and Releases
The United States Shares 500 Million COVID-19 Vaccine Doses Worldwide
Antony J. Blinken March 17, 2022

The United States has now shared over 500 million safe and effective COVID-19 vaccine doses, free of cost, to more than 110 countries and economies around the world – for the sole purpose of saving lives.

Since the start of the pandemic, we have provided nearly $20 billion in health, humanitarian, economic, and development assistance to over 120 countries, including rapid response support for urgent health needs and technical assistance to expand vaccine access. We have also invested and supported the expansion of regional COVID-19 vaccine manufacturing in Africa and Asia. Today, we continue to work tirelessly with governments and international organizations, vaccine producers, NGOs, the private sector, and others to deliver vaccines, get shots in arms, increase testing and treatment, support and protect healthcare workers, and more. Our recently announced COVID-19 Global Action Plan provides a clear roadmap for this international coordination...

USAID Announces an Additional $12.8 million in Assistance to Malawi
March 18, 2022
The U.S. Government, through the United States Agency for International Development (USAID), has announced an additional $12.8 million in assistance for Malawi to tackle food insecurity, strengthen anti-corruption efforts and respond to Tropical Cyclone Ana.

Marking Delivery of Half a Billion U.S.-Donated COVID-19 Vaccines
March 17, 2022
Today, the United States has delivered half a billion COVID-19 vaccines, all donated free of charge, to more than 110 countries in every region of the world—more doses than any other nation. For every shot we have given in the United States, nearly one has been shipped abroad. Today marks an important milestone in reaching President Biden’s extraordinary pledge to donate more than 1.2 billion safe and effective shots worldwide, with no expectations in return.

The United States Announces nearly $585 Million in New Humanitarian Assistance for the People of Yemen as Crisis Threatens Millions of Lives
March 16, 2022
Today, the U.S. Secretary of State Antony Blinken announced nearly $585 million in humanitarian assistance for the people of Yemen at the 2022 High-Level Pledging Event for the Humanitarian Crisis in Yemen. In recent weeks, life-saving humanitarian programs in Yemen have been halted or forced to scale back significantly due to a lack of resources. This newly announced funding will enable continued provision of life-saving aid for Yemen’s most vulnerable people amid the intensifying conflict and the country’s devastating economic deterioration. The United States remains one of the largest donors of
humanitarian assistance to Yemen, providing nearly $4.5 billion since the conflict began seven years ago.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency
News & Press Releases
Press Releases
No new digest content identified.

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates [Selected]
Publication
Guidance for the prevention and control of COVID-19 in temporary reception centres in the context of the large numbers of people fleeing Ukraine
Technical report - 18 Mar 2022

News
COVID-19 testing, vaccination and implementation of protective measures recommended for reception centres of displaced people from Ukraine

European Centre for Disease Prevention and Control
COVID-19 Vaccine Tracker

Cumulative vaccine uptake (%) in the total population in EU/EEA countries

<table>
<thead>
<tr>
<th></th>
<th>At least one dose</th>
<th>Primary course</th>
<th>Booster/additional dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>75.2%</td>
<td>72.2%</td>
<td>52.1%</td>
<td></td>
</tr>
</tbody>
</table>

Accessed 19 Mar 2022

European Commission
Ukraine refugees: Operational guidelines to support Member States in applying the Temporary Protection Directive
Today, the Commission is presenting operational guidelines to support Member States in applying the Directive. Russian and Belarussian oligarchs, has now stepped up its action at international level.

Yemen: Commission pledges €154 million for conflict-affected people
The European Commission has today announced €154 million for 2022 to support those most in need in Yemen at the high-level pledging event for Yemen co-hosted by the United Nations, Sweden and Switzerland.

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine”
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

COVID-19 India as on: 19 March 2022, 08:00 IST (GMT+5:30)
(11 Status change since yesterday)

Active: 27802 (0.06%)
Discharged: 42461926 (98.73%)
Deaths: 516352 (1.20%)

Total Vaccination: 1,81,04,96,924 (5,84,177↑)
- 78.22 cr Total Tests conducted so far; 3,70,514 tests conducted in the last 24 hours

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

:::::::
:::::::

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[See China CDC below]

:::::::
:::::::
:::::::

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)
https://polioeradication.org/polio-today/polio-today/polio-now/this-week/

Polio this week as of 16 March 2022

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
– DR Congo: three cVDPV2 cases
– Nigeria: one cVDPV2 case

:::::::
:::::::

Disease Outbreak News (DONs)
No new reports identified.

:::::::
:::::::

WHO/OCHA Emergencies

Editor’s Note:
WHO has issued a single situation report on Ukraine [5 March 2022, Emergency in Ukraine – Situation Report 1] which we featured in last week’s edition. Ukraine has not yet been listed in the omnibus inventory on WHO emergencies below.

Health emergencies list - WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”

**Afghanistan crisis**

Measles vaccination campaign kicks off in Afghanistan to fight ongoing outbreak: around 1.2 million children in 24 provinces to get vaccinated  14 March 2022

**Crisis in Northern Ethiopia** [Last apparent update: 1 June 2021]

**Ebola outbreak, Democratic Republic of the Congo, 2021** [Last apparent update: 17 Aug 2021]

**Ebola outbreak outbreak, N’Zerekore, Guinea, 2021** [Last apparent update: 17 Aug 2021]

**Coronavirus disease (COVID-19) pandemic** [See COVID above]

**Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020**
[Last apparent update: 17 Aug 2021]

**Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020**
[Last apparent update: 17 Aug 2021]

**Ebola outbreak, Democratic Republic of the Congo, 2018** [Last apparent update: 24 July 2018]

**Yemen crisis** [Last apparent update: 12 February 2021]

**Syria crisis** [Last apparent update: 18 June 2021]

**Somalia crisis** [Last apparent update: 24 March 2018]

**Nigeria crisis** [Last apparent update: 1 Oct 2021]

**Ebola outbreak, Democratic Republic of the Congo, 2017** [Last apparent update: 17 Aug 2021]

**Zika virus disease outbreak, 2015-2016** [Last apparent update: 24 Jan 2020]


**Iraq crisis** [Last apparent update: 9 Jan 2008]

**South Sudan crisis** [Last apparent update: 23 Sep 2020]

**Avian influenza A (H7N9) virus outbreak** [Last apparent update: 13 September 2021]

**Middle East respiratory syndrome (MERS-CoV) outbreak** [Last apparent update: 8 July 2019]

**Influenza A (H1N1) virus, 2009-2010 pandemic** [Last apparent update: 10 Aug 2010]
UN OCHA – Current Emergencies

Current Corporate Emergencies

Afghanistan
No new updates identified.

Northern Ethiopia

Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 17 March 2022

HIGHLIGHTS

- With the Meher planting season a month away, only 4,000 tonnes of improved seed (of 49,000 tonnes required) is available in Tigray.
- Thanks to the batch received through UNHAS, 117,870 animals were vaccinated during the reporting period, and 2.93 million vaccinated since 7 July 2021 in Tigray (24% of target).
- Only 5 of 100 large rubber tents required in Jara IDP site in North Wollo Zone, Amhara are in place. Additional plastic sheets also required for 150,000 IDPs to be relocated there.
- 11 schools are sheltering IDPs in Afdera and Kori woredas in Afar and an additional 198 schools remain closed due to insecurity, impacting more than 48,000 children.

Ukraine

Ukraine: Humanitarian Impact Situation Report (As of 3:00 p.m. (EET) on 18 March 2022)

:: Now in its fourth week, the ongoing military offensive has already caused 2,149 civilian casualties, including 816 killed, according to the Office of the High Commissioner for Human Rights (OHCHR). The actual figures are likely much higher as fierce clashes continue across the country.

WHO & Regional Offices [to 19 Mar 2022]
https://www.who.int/

News [Selected]
15 March 2022
Departmental news
WHO and Kuaishou Technology provide access to COVID-19 information and mental health tips

14 March 2022
Departmental news
WHO released a new operational guide to promote COVID-19 vaccination uptake and tackle vaccine hesitancy among refugees and migrants

13 March 2022
Statement
Stop attacks on health care in Ukraine

WHO Director General Speeches [selected]
WHO Director-General’s remarks at United Nations Security Council meeting on Ukraine – 17 March 2022

WHO Director-General’s keynote speech at the Thailand International Health Expo 2022 - 17 March 2022

WHO Director-General’s opening remarks at the Member State Information Session on COVID-19 - 17 March 2022

WHO Director-General's opening remarks at the 28th Tripartite Executive Annual Meeting Tripartite Joint Secretariat on AMR – 17 March 2022

WHO Director-General's opening remarks at the WHO press conference – 16 March 2022

WHO Director-General's closing remarks at the High-level pledging event for the humanitarian crisis in Yemen – 16 March 2022

WHO Director-General’s remarks at the 4th Meeting of Global Leaders Group on AMR – 16 March 2022

:: More than 80 million doses to be administered to southern African children targeted in mass polio vaccination drives 18 March 2022
:: Africa’s COVID-19 vaccine uptake increases by 15% 17 March 2022

As cases rise in other regions, the Americas must focus on vaccines to protect the most vulnerable
While many countries and territories in the region are on track to reach 70% coverage for COVID-19 vaccines, 21 have yet to reach half their populations. Washington D.C., 16 March 2022 (PAHO) – As COVID-19 vaccination continues to expand in the Americas, countries must continue to focus on the protection of the most vulnerable, such as the...

**WHO South-East Asia Region SEARO**
*No new digest content identified*

**WHO European Region EURO**
:: Hungary: the importance of mental health and psychosocial support to refugees and displaced people – one mother’s story of a life upended through the Ukraine war 18-03-2022
:: Prioritizing the health of refugees and migrants: an urgent, necessary plan of action for countries and regions in our interconnected world 18-03-2022
:: The impacts of war on children with cancer – ensuring continuation of care for those whose lives depend on it 16-03-2022
:: Romania: civil society on the front line of health-care provision to refugees from Ukraine 15-03-2022

**WHO Eastern Mediterranean Region EMRO**
:: High-level delegation of WHO visits Iraq to boost health system 16 March 2022
:: Measles vaccination campaign begins in Afghanistan to fight ongoing outbreak 14 March 2022
:: Integrated public health teams helping Sudan move forward on polio transition 13 March 2022

**WHO Western Pacific Region**
*No new digest content identified*

::::

**WHO Events**
https://www.who.int/news-room/events/1
[Selected]
**COVID-19 Case Management Webinar Series: COVID-19 in children and young persons**
22 March 2022 13:30 – 15:30 CET

**21st meeting of the Malaria Policy Advisory Group (MPAG)**
23 – 24 March 2022

*World TB Day*
**World TB Day 2022: Invest to End TB. Save Lives**
24 March 2022

::::

**New WHO Publications**
https://www.who.int/publications/i
Selected Titles
17 March 2022
**Emergency in Ukraine: external situation report #3, published 17 March 2022: reporting period: 11–16...**
15 March 2022
**Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac**

15 March 2022
**Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: Grading of...**

15 March 2022
**Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National...**

15 March 2022
**Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against...**

15 March 2022
**Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19**

15 March 2022
**Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca...**

15 March 2022
**Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19...**

14 March 2022
**Strengthening COVID-19 vaccine demand and uptake in refugees and migrants**

14 March 2022
**Virtual cGMP Training Marathon for Vaccine Manufacturing: Questions & Answers**

CDC/ACIP [U.S.] [to 19 Mar 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases, Announcements [Selected]
No new digest content identified.

ACIP Meetings
Next meeting scheduled for June 22-23, 2022
Coronavirus Disease 2019 (COVID-19)- CDC

Approximately 25 announcements/reports/data summaries.
:: 3/18/22 COVID-19 vaccines continue to protect against hospitalization and death among adults
:: 3/18/22 COVID-19 vaccines continue to protect against hospitalization and death among adults
:: 3/17/22 The Advisory Committee on Immunization Practices’ Recommendation for Use of Moderna
COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
:: 3/17/22 Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

Africa CDC  [to 19 Mar 2022]
http://www.africacdc.org/

News

Outbreak Brief 113: Coronavirus Disease 2019 (COVID-19) Pandemic
Date of Issue: 14 March 2022

... As of 6 p.m. East African Time (EAT) 14 March 2022, a total of 11,283,362 COVID-19 cases and 250,393 deaths (CFR: 2.2%) have been reported by the 55 African Union (AU) Member States (MS). This represents 3% of all cases and 4.1% of all deaths reported globally. Thirty-four (62%) AU MS are reporting CFRs higher than the global CFR. Since the detection of COVID-19 on the African continent in February 2020, 53 (96%) AU MS have experienced three COVID-19 waves, 47 (72%) countries have experienced four waves and nine countries have experienced five waves. One country (Mauritius) is currently experiencing a sixth wave. Figure 1 shows the trend of new COVID-19 cases reported per day by the AU region from 15 February 2020 to 14 March 2022. Despite a test positivity rate of 11.2%, the daily reported number of new cases across the continent is on a downward trend. More information on the COVID-19 situation in Africa is available on the Africa CDC daily dashboard and hotspot dashboard.
March 19: Daily briefing on novel coronavirus cases in China
On March 18, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 2,228 new cases of confirmed infections.

Chinese mainland reports 2,388 new local COVID-19 cases
2022-03-18
The Chinese mainland on Thursday reported 2,388 locally transmitted COVID-19 cases, up from 1,226 on Wednesday, the National Health Commission said on March 18.

Preplanned Studies: Acceptability of Tuberculosis Preventive Treatment Strategies Among Healthcare Workers Using an Online Survey — China, 2021

Preplanned Studies: The Impact of COVID-19 Epidemic on Tuberculosis Reports Among Students — Guizhou Province, China, 2020

Preplanned Studies: Application of Disability-Adjusted Life Years to Evaluate the Burden and Trend of Tuberculosis — China, 1990–2019

Organization Announcements

Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity [to 19 Mar 2022]
https://www.airfinity.com/insights
INSIGHTS & COMPANY NEWS
No new digest content identified.

Paul G. Allen Frontiers Group [to 19 Mar 2022]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation [to 19 Mar 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
Press release
Mar 14, 2022
Novo Nordisk Foundation, Open Philanthropy, and Bill & Melinda Gates Foundation Launch Initiative to Support New Antiviral Medicines for Future Pandemics
Global initiative will accelerate the discovery and development of antiviral drug candidates that can be distributed quickly and equitably next time the world faces a pandemic threat
COPENHAGEN – SAN FRANCISCO – SEATTLE (March 14, 2022) – Today, the Novo Nordisk Foundation, Open Philanthropy, and the Bill & Melinda Gates Foundation announced an initial commitment of up to $90 million of coordinated funding toward Pandemic Antiviral Discovery (PAD), a new initiative to catalyze discovery and early development of antiviral medicines for future pandemics. With equitable access as a core principle of the initiative, the founding partners are committed to ensuring that discoveries and innovations supported by PAD are accessible to people in low- and middle-income countries...

Bill & Melinda Gates Medical Research Institute [to 19 Mar 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 19 Mar 2022]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 19 Mar 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Informed Consent: A Monthly Review – March 2022 is now posted here
:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.
:: Statement on ICF [Informed Consent Form] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse

CEPI – Coalition for Epidemic Preparedness Innovations  [to 19 Mar 2022]
http://cepi.net/
Latest News
Nipah survivors study to advance new vaccines against highly fatal threat
15 Mar 2022  By CEPI
- CEPI will expand its partnership with icddr,b in Bangladesh, providing near to an additional $1 million in funding to advance understanding of the Nipah virus.
- Nipah virus remains one of the deadliest infections known to infect humans, however no vaccines are currently licensed for use.
- Research will also support the development of key tools needed for upcoming CEPI-supported and other Nipah vaccine clinical trials and potential future regulatory review.

DARPA – Defense Advanced Research Projects Agency [U.S.]  [to 19 Mar 2022]
https://www.darpa.mil/news
News
3/3/2022
Developing Algorithms that Make Decisions Aligned with Human Experts
Military operations – from combat, to medical triage, to disaster relief – require complex and rapid decision-making in dynamic situations where there is often no single right answer. Two seasoned military leaders facing the same scenario on the battlefield, for example, may make different tactical decisions when faced with difficult options. As AI systems become more advanced in teaming with humans, building appropriate human trust in the AI’s abilities to make sound decisions is vital.

Duke Global Health Innovation Center  [to 19 Mar 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP  [to 19 Mar 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.

News
No new digest content identified.

Emory Vaccine Center [to 19 Mar 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 19 Mar 2022]
http://www.euvgaccine.eu/
Latest News, Events
No new digest content identified.

Evidence Aid [to 19 Mar 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
New Resources
Professional interpreters can help in the care of hospitalized children from migrant and refugee families Added March 18, 2022
Focused psychosocial interventions for children in low-resource humanitarian settings Added March 17, 2022
Eastern European migrants’ use and experience of UK healthcare services (search done in February 2017) Added March 16, 2022

Fondation Mérieux [to 19 Mar 2022]
http://www.fondation-merieux.org/
News, Events
Mérieux Foundation co-organized event
2nd Workshop of the Global Collaboration on Advanced Vaccinology Training
March 22 - 24, 2022 - Centre des Pensières, Veyrier-du-Lac (France)
From March 22-24, 2022, the second Workshop of the Global Collaboration on Advanced Vaccinology Training will be held at Les Pensières Center for Global Health, with approximately 70 participants.

Gavi [to 19 Mar 2022]
https://www.gavi.org/
No news releases identified.

**GHIT Fund**  [to 19 Mar 2022]
https://www.ghitfund.org/newsroom/press
No new digest content identified.

**Global Fund**  [to 19 Mar 2022]
*News & Stories*

**Update on the RTS,S Malaria Vaccine**
17 March 2022
The Global Fund’s malaria Strategic Initiative, alongside Gavi and Unitaid, continues to fund the Malaria Vaccine implementation program to generate further evidence on the RTS,S vaccine’s impact, safety, and feasibility over the next two years.

**Global Health Supply Chain Dialogue**
17 March 2022
The Global Fund is organizing a Global Health Supply Chain Dialogue from 29 to 31 March 2022 under the theme “Building Resilient Supply Chains for Effective Pandemic Preparedness”. The conference aims to foster discussion between countries and partners on NEXTGen market shaping strategies, and generate commitment to an action plan that will strengthen public health supply chains, an essential element in the path to more resilient health systems.

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]**  [to 19 Mar 2022]
https://www.glopid-r.org/news/
*News*

**Upcoming webinar: Response to COVID-19 vaccine in patients with a hematological condition and primary immunodeficiencies**
07/03/2022
The second webinar in the ZonMw series ‘Response to COVID-19 vaccine in patients with a hematological condition and primary immunodeficiencies’... Monday April 4, 2022, from 5pm to 6pm CET.

**Hilleman Laboratories**  [to 19 Mar 2022]
http://www.hilleman-labs.org/
*News & Insights*
No new digest content identified

**HHMI - Howard Hughes Medical Institute**  [to 19 Mar 2022]
https://www.hhmi.org/news
*Press Room*
Human Vaccines Project  [to 19 Mar 2022]
http://www.humanvaccinesproject.org/
News
Press Release
Mar 18, 2022
Michelson Philanthropies and Science Reveal the Next Innovators in Immunology

IAVI  [to 19 Mar 2022]
https://www.iavi.org/
Latest News
March 17, 2022
HVTN 302 begins first dosing of mRNA HIV vaccine antigens
HVTN, NIAID, and Moderna partner on trial of HIV Env trimers designed by IAVI's William Schief.

ICRC  [to 19 Mar 2022]
What’s New
ICRC President: The suffering in Mariupol must not become the future of Ukraine
The following is a statement from Peter Maurer, the president of the International Committee of the Red Cross (ICRC), who is currently in Ukraine: Kyiv (ICRC) – Driving toward Kyiv this week, the signs of conflict grew.
17-03-2022 | News release

Yemen: Even as global attention shifts, the world must not abandon Yemen
Seven years of raging conflict in Yemen has exhausted the population’s capacity to cope, even as global attention is shifting toward other high-profile crises.
17-03-2022 | News release

ICRC President makes four calls at High-level Pledging Conference for the Humanitarian Crisis in Yemen
ICRC President Peter Maurer makes four calls regarding the conflict in Yemen at High-level Pledging Conference for the Humanitarian Crisis in Yemen
17-03-2022 | Statement

Horn of Africa: Alarming situation as hundreds of thousands of Somalis suffer from the most severe drought in the last decade
Somalia is the most severely affected of the countries facing the ongoing drought in the Horn of Africa. The situation is alarming, and it is deteriorating. People are massively abandoning their homes in search for water and food.
16-03-2022 | News release

International Coalition of Medicines Regulatory Authorities [ICMRA]
IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC  [to 19 Mar 2022]
Selected Press Releases, Announcements
17/03/2022
**IFRC urges countries in the Caribbean to build vaccine confidence in communities**
Jamaica, 17 March 2022 - The low rate of vaccination against COVID-19 in the Caribbean must be addressed through building confidence among the population as well as responding to the inequity of vaccine access, says the International Federation of the Red Cross and Red Crescent Societies (IFRC).

Building this confidence is a key factor in promoting universal vaccination and therefore fostering socio-economic recovery in the Caribbean, where only 40 per cent of the population counts with a complete scheme of vaccination, in comparison with 68 per cent in South America and 60 per cent in Central America. In the Americas region more than 1.7 billion COVID-19 vaccine doses have been administered...

16/03/2022
**Philippines: 2 million exposed to climate disasters 3 months after Typhoon Rai**

Institut Pasteur  [to 19 Mar 2022]
Press Documents
Press release
14.03.2022
**Discovery of an immune escape mechanism promoting Listeria infection of the central nervous system**
Some "hypervirulent" strains of Listeria monocytogenes have a greater capacity to infect the central nervous system....

IOM / International Organization for Migration  [to 19 Mar 2022]
News - Selected
No new digest content identified.

ISC / International Science Council  [to 19 Mar 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

**News**  **Blogs**  **Podcasts**  **Events**

No new digest content identified.

**IVAC**  [to 19 Mar 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

**Updates; Events**

**Webinar: Reaching Zero-dose Children and Supporting Immunization Equity in Humanitarian Contexts**
March 2022
When: March 28th from 8:00-9:00am
When: March 28th from 8:00-9:00am

**IVI**  [to 19 Mar 2022]
http://www.ivi.int/

**IVI News & Announcements**

**IVI welcomes the United Arab Emirates as its 37th member state with flag-raising ceremony**
March 17, 2022 – SEOUL, South Korea – The International Vaccine Institute (IVI) announced today that the United Arab Emirates (UAE) joined IVI, becoming the international organization’s 37th member state. His Excellency Abdulla Saif Al Nuaimi, Ambassador of the UAE to the Republic of Korea, raised the flag of the UAE at IVI headquarters...

**Johns Hopkins Center for Health Security**  [to 19 Mar 2022]
https://www.centerforhealthsecurity.org/news/center-news/

**Center News**
No new digest content identified.

**MSF/Médecins Sans Frontières**  [to 19 Mar 2022]
http://www.msf.org/

**Latest [Selected Announcements]**

**Central American Migration**

**Peru: Venezuelan migrants struggle to survive**
Project Update 18 Mar 2022

**War in Ukraine**

**Staff in major Kyiv hospital receive training for potential increase in casualties**
Project Update 18 Mar 2022

Ethiopia Tigray crisis
Ethiopia: MSF seeks answers from government after new media report on killing of its staff
Statement 17 Mar 2022

War in Ukraine
War in Ukraine has displaced me twice and I’m on the road again
Voices from the Field 16 Mar 2022

War in Ukraine
Every day thousands of Ukrainians arrive in Slovakia – traumatised and exhausted
Interview 14 Mar 2022

National Academy of Medicine - USA [to 19 Mar 2022]
https://nam.edu/programs/
News
Statement by NAM President Victor Dzau on Responding to the Health Crisis In and Around Ukraine
March 15, 2022
I have been watching with increasing sadness and alarm as health care facilities come under fire during Russia’s invasion of Ukraine with devastating impacts on patients, civilians, and frontline workers. Earlier this week, the World Health Organization confirmed at least 31 such attacks, including the shelling of a children's and maternity hospital. Many facilities are [...]

National Academy of Sciences - USA [to 19 Mar 2022]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 19 Mar 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
Vaccines Federal Implementation Plan 2021-2025
On Wednesday March 2, 2022, the U.S. Department of Health and Human Services (HHS) published a Request for Information (RFI) to solicit stakeholder written public comments on the draft Vaccines Federal Implementation Plan 2021-2025- PDF*. HHS values input from all stakeholders and will take all public comments into consideration before finalizing this document.
We encourage your input or comments and ask that you circulate this information to others who may also wish to provide comments. Information about how to provide written public comment is found on HHS.gov and the deadline for submissions is 5 p.m. EST Tuesday March 29, 2022.
The Vaccines Federal Implementation Plan is a companion document to the Vaccines National Strategic Plan 2021-2025 published in January 2021. This plan outlines the federal government’s broad national vaccination goals and offers a framework to eliminate vaccine-preventable diseases through safe and effective vaccination over the lifespan, for both federal agencies and external partners.
The implementation plan focuses on the specific actions that federal agencies can take to further those same national vaccination goals.

NIH [to 19 Mar 2022]
News Releases
NIH’s All of Us Research Program Releases First Genomic Dataset of Nearly 100,000 Whole Genome Sequences
March 17, 2022 — Contributions from diverse participants set to change the landscape of genomics research.

NIH launches clinical trial of three mRNA HIV vaccines
March 14, 2022 — Phase 1 study is among first to examine mRNA technology for HIV.

OECD [to 19 Mar 2022]
http://www.oecd.org/newsroom/publicationsdocuments/bydate/
Newsroom
OECD calls for well-targeted support to the vulnerable as war undermines global recovery
Russia’s war against the people of Ukraine is a deeply distressing moment for the world. Thousands of people have been killed with millions fleeing from the war. Beyond the ongoing humanitarian disaster, the economic damage is already being felt worldwide and risks becoming increasingly severe. 17-March-2022

OXFAM [to 19 Mar 2022]
https://www.oxfam.org/en/
Press Releases
Media reaction in response to reports of a compromise on the vaccines TRIPS waiver
16 March 2022
[See Perspectives above for deatil]

PATH [to 19 Mar 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

Sabin Vaccine Institute [to 19 Mar 2022]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 19 Mar 2022]
http://www.unaids.org/en
18 March 2022

**UNAIDS staff member talks about the invasion of Ukraine**

17 March 2022

**Supporting the HIV response for young people in Eswatini**

15 March 2022

**Social enterprises and financial saving supporting Madagascan sex workers through COVID-19**

14 March 2022

**UNAIDS Executive Director’s Statement at the 65th session of the Commission on Narcotic Drugs**

14 March 2022

**Discriminatory attitudes remain common**

---

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 19 Mar 2022]


**Selected News Releases, Announcements**

18 Mar 2022

**UNHCR and partners seek US$1.2 billion to address Africa’s largest refugee crisis**

18 Mar 2022

**UNHCR warns of rising needs in Ukraine and neighbouring countries, calls for cessation of hostilities**

18 Mar 2022

**Poland welcomes more than two million refugees from Ukraine**

18 Mar 2022

---

**UNICEF** [to 19 Mar 2022]

https://www.unicef.org/media/press-releases

**Press Releases, News Notes, Statements [Selected]**

News note

03/18/2022

**UNICEF sends additional life-saving supplies for Ukraine response**


NEW YORK, 18 March 2022 –, As of 17 March 2022, UNICEF has dispatched 85 trucks carrying 858 tons of emergency supplies to support children and families in war-torn Ukraine and neighbouring countries. Out of this total, 78 trucks carrying over 780 tons were sent to Ukraine while the remaining 7 trucks were sent to nearby countries. A total of 34 trucks have already arrived...

Remarks

03/16/2022
Remarks by UNICEF Executive Director Catherine Russell at the high-level pledging event on the humanitarian crisis in Yemen
While public attention on Yemen waxes and wanes amid other global crises, the brutal war continues unabated. Yemen has become a living hell for children. Millions of parents don’t know if their children will survive from one day to the next. More than 10,200 children have been killed or injured. Ongoing violence, mines and explosive remnants of...

Remarks
03/15/2022
"Particularly shocking" - Every single minute, 55 children have fled their country. A Ukrainian child has become a refugee almost every single second since the start of the war.
GENEVA, 15 March 2022 - , "Since February 24, scores of children have been killed in Ukraine. Many more have been injured. "And more than 1.5 million children have fled the country. "Putting this last statistic another way, on average, every day in Ukraine from the start of the war, more than 75,000 children have become refugees. Every day. "This last number is...

Press release
03/15/2022
Syria: children struggle with physical and psychological scars after 11 years of war
DAMASCUS, 15 March 2022, – Eleven years since the crisis began in Syria, violence, displacement, and lack of access to essential services continue to put children’s lives at risk. Just yesterday, three children were reportedly killed by unexploded ordnance in Aleppo city. Last year, nearly 900 children in Syria lost their lives or were injured. This brings the total..., ######, Notes for editors, More than 14.6 million Syrians require humanitarian assistance. This includes 5.3 million internally displaced persons. In 2021, UNICEF reached 11.3 million people, including 7.3 million children with humanitarian assistance across Syria. UNICEF and partners provided 220,892 children with mental health and psychosocial support services through...

Press release
03/14/2022
Yemen: Acute hunger at unprecedented levels as funding dries up
SANA’A, ADEN, ROME, NEW YORK, 14 March 2022, - Yemen’s already dire hunger crisis is teetering on the edge of outright catastrophe, with 17.4 million people now in need of food assistance and a growing portion of the population coping with emergency levels of hunger, UN agencies have warned. The humanitarian situation in the country is poised to get even worse between June and December 2022...

Statement
03/13/2022
Stop attacks on health care in Ukraine
NEW YORK/GENEVA, 13 March 2022 — "Today, we call for an immediate cessation of all attacks on health care in Ukraine. These horrific attacks are killing and causing serious injuries to patients and health workers, destroying vital health infrastructure and forcing thousands to forgo accessing health services despite catastrophic needs. "To attack t

**Unitaid** [to 19 Mar 2022]
https://unitaid.org/

**Featured News**
18 March 2022
**Unitaid to introduce new long-lasting injection to prevent HIV in Brazil and South Africa, as high-income countries begin deployment**
- Unitaid will fund implementation of the latest innovation in HIV prevention – an injectable version of pre-exposure prophylaxis (PrEP) that has shown to be more effective than daily oral PrEP in reducing the risk of HIV infection, with just six injections a year.
- United Nations' targets to reach three million people with PrEP by 2020 were missed by two-thirds. Long-acting cabotegravir provides a new alternative that addresses challenges associated with oral PrEP including inconsistent use and fear of stigma or discrimination, and could extend benefits to millions of people at risk of HIV infection.
- Unitaid, in partnership with Fiocruz in Brazil, Wits RHI in South Africa, and local health authorities in both countries, will integrate long-acting PrEP into national sexual health programmes and generate crucial real-world evidence that will underpin efforts for rapid global scale-up.
- Parallel action is urgently required to secure broader access for long-acting cabotegravir so 2025 UN prevention targets to reach 95% of people at risk of infection can be achieved

17 March 2022
**Unitaid commits US$ 56 million to boost access to medical oxygen globally, calls on other donors to close US$ 1 billion gap**
- New investments will boost access to medical oxygen globally and save lives during the COVID-19 pandemic and beyond
- In low- and middle-income countries, these grants will increase liquid oxygen supplies, lower costs, strengthen infrastructure, expand technical capacity, and ensure the safe use of medical oxygen
- Oxygen remains a critical component of the global COVID-19 response – 75% of patients hospitalized for COVID-19 can be treated with oxygen alone — without any other advanced care
- Oxygen is a high-return lifesaving treatment, a hallmark of functional health systems. Investments now will save lives for years to come. But access to oxygen still does not meet needs for COVID-19 and/or other serious illnesses
- Unitaid calls on donors to close the ~US$ 1 billion gap in the oxygen response, building on the ~US$ 700 million investments by the Access to COVID-19 Tools Accelerator Oxygen Emergency Taskforce partners since the beginning of 2021

**Vaccine Equity Cooperative [nee Initiative]** [to 19 Mar 2022]
https://vaccineequitycooperative.org/news/

**News**

No new digest content identified.
Vaccination Acceptance & Demand Initiative [Sabin] [to 19 Mar 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

Vaccine Confidence Project [to 19 Mar 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 19 Mar 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust [to 19 Mar 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
New funding calls aim to improve mental health interventions
17 March 2022
Some mental health treatments and interventions are effective. Others aren’t. And there’s still little to no understanding of why, or how to improve the outlook for anxiety, depression and psychosis. New Wellcome funding aims to address that.

The Wistar Institute [to 19 Mar 2022]
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 19 Mar 2022]
https://www.wfpha.org/
Latest News - Blog
No new digest content identified.

World Bank [to 19 Mar 2022]
Selected News, Announcements
Monitoring COVID-19 impacts on Latin American and Caribbean Households
To respond swiftly to the growing demand for data to monitor the welfare impacts of COVID-19 on households, the World Bank and various partners embarked on an initiative to implement High-Frequency Phone...
**Additional Financing of $25 Million to Boost COVID-19 Vaccine Rollout in Tajikistan, with World Bank Support**

DUSHANBE, March 14, 2022 – The Government of Tajikistan and the World Bank signed today a $25 million grant agreement as additional financing to the Tajikistan Emergency COVID-19 Project, which has been...
**BIO** [to 19 Mar 2022]
Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 19 Mar 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

**ICBA – International Council of Biotechnology Associations** [to 19 Mar 2022]
https://internationalbiotech.org/news/
News
**ICBA Statement on Leaked QUAD Proposal for a COVID-19 Vaccine IP Rights Waiver** [undated]
Steve Bates Chair of ICBA said “The leaked QUAD proposal of a waiver on intellectual property rights for COVID vaccines would, if agreed, have a chilling impact on investment into the small companies that have been at the heart of the solutions to COVID-19. It would do nothing to solve the challenges we face in 2022 and make it far harder for small companies pioneering in this space in future”

“Small biotechs throughout ICBA member countries, including, for example, companies such as Canada-based Acuitas Therapeutics, BioNtech from Germany and the UK’s Vaccitech, all depend on their intellectual property to deliver key innovations that underpin the current generation of COVID -19 vaccines. Alongside these successes are many, many companies in our community that invested heavily and failed to make breakthroughs. This proposal directly threatens this innovative ecosystem’s ability to attract the capital needed to develop next generation of vaccines whilst doing nothing to solve the access challenges we have in 2022.”

“The reported proposal misguided casts IP as a barrier to COVID-19 vaccine access and distribution despite there being abundant supply of COVID-19 vaccines given the collective manufacturing globally of over 11 billion doses in 2021. Weakening IP rights does nothing to facilitate the distribution of these manufactured vaccines to people around the world who most need them – rather prioritizing addressing healthcare infrastructure and vaccine hesitancy in the developing world would lead to more shots in arms.”

**IFPMA** [to 19 Mar 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
**IFPMA statement on TRIPS discussion document**
16 March 2022
[See Perspectives above for detail]
PhRMA Statement on the War in Ukraine

WASHINGTON, D.C. (March 16, 2022) – The Pharmaceutical Research and Manufacturers of America released the following statement on the war in Ukraine:

“We are deeply saddened by the war taking place against the people of Ukraine. The biopharmaceutical research industry is united in our mission of providing vaccines and treatments to all patients who need them. Like the broader health care sector, biopharmaceutical companies serve a critical humanitarian role in sustaining access to medicines and clinical trials for patients wherever they are. PhRMA’s member companies are working in a variety of ways to support those affected by this humanitarian crisis, including by providing free essential medicines, making monetary donations to non-profits providing aid, monitoring for supply chain disruptions, and addressing the safety of employees and their families through financial assistance, transportation and other resources.

“We condemn the violence unfolding against the people of Ukraine and hope for its immediate end.”

To learn more about individual company efforts, please visit the website set up by our European sister association, the European Federation of Pharmaceutical Industries and Associations’ (EFPIA), found here.

* * * * *

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Emergencies
:: Organization Announcements
:: Journal Watch
**Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of the themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

**AJOB Empirical Bioethics**
Volume 13, 2022 Issue 1
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

**AMA Journal of Ethics**
Volume 24, Number 2: E107-163 Feb 2022

**Tactical Health and Law Enforcement**
Tactical health involves providing field-based clinical support to law enforcement operations during frontline crisis interventions and prehospital emergency care. Health professional skill can inform individual officers’ occupational health maintenance and help agents of the state navigate primary and secondary trauma and posttrauma experiences in field- and clinic-based settings. Tactical health expertise can also inform department- and agency-level policies, decisions, and responses to community health and safety threats. Ethical questions considered in this issue focus on the nature and scope of health professionals’ collaborations with law enforcement personnel during and following critical event preparation and responses.

**American Journal of Infection Control**
March 2022 Volume 50 Issue 3 p243-366
http://www.ajicjournal.org/current
[Reviewed earlier]

**American Journal of Preventive Medicine**
March 2022 Volume 62 Issue 3 p307-472
https://www.ajpmonline.org/current
[Reviewed earlier]

**American Journal of Public Health**
**American Journal of Tropical Medicine and Hygiene**
Volume 106 (2022): Issue 2 (Feb 2022)
https://www.ajtmh.org/view/journals/tpmd/106/2/tpmd.106.issue-2.xml
[Reviewed earlier]

**Annals of Internal Medicine**
March 2022 Volume 175, Issue 3
http://annals.org/aim/issue

*Original Research*
**COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System - A Target Trial Emulation Study**
FREE
George N. Ioannou, BMBCh, MS, Emily R. Locke, MPH, Ann M. O'Hare, MD, ... *et al.*
Pages: 352–361

**Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine - A Case–Control Study**
FREE
Francisco Tsz Tsun Lai, PhD, Xue Li, PhD, Kuan Peng, MHS, Lei Huang, MSc, Patrick Ip, MPH, ... *et al.*
Pages: 362–370

**SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis**
FREE
Shuchi Anand, MD, Maria E. Montez-Rath, PhD, Jialin Han, MS, Pablo Garcia, MD, LinaCel adden, CLS, ... *et al.*
Pages: 371–378

**Artificial Intelligence – An International Journal**
Volume 304 March 2022
[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**
http://resource-allocation.biomedcentral.com/
(Accessed 19 Mar 2022)
[No new digest content identified]
On the accuracy of short-term COVID-19 fatality forecasts

Forecasting new cases, hospitalizations, and disease-induced deaths is an important part of infectious disease surveillance and helps guide health officials in implementing effective countermeasures. For disease...

Authors: Nino Antulov-Fantulin and Lucas Böttcher
Citation: BMC Infectious Diseases 2022 22:251
Content type: Research article Published on: 14 March 2022

Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization

Safety after the second dose of the SARS-CoV-2 vaccine remains to be elucidated, especially among individuals reporting adverse events after their first dose. This study aims to evaluate the impact of a delay...

Authors: Carlos King Ho Wong, Xi Xiong, Kristy Tsz Kwan Lau, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Xue Li, Esther Wai Yin Chan, Eric Yuk Fai Wan, Ivan Chi Ho Au, Benjamin John Cowling, Cheuk Kwong Lee and Ian Chi Kei Wong
Citation: BMC Medicine 2022 20:119
Content type: Research article Published on: 17 March 2022
Public knowledge, attitude, and acceptance toward COVID-19 vaccines in Palestine: a cross-sectional study

The consequences of the COVID-19 pandemic on physical and mental health in addition to the global economy are huge. Vaccination is a pivotal measure to decrease COVID-19 morbidity and mortality and to help bri...


Citation: BMC Public Health 2022 22:529

Content type: Research Published on: 17 March 2022

Public perception of isolation, quarantine, social distancing and community containment during COVID-19 pandemic

Effective strategies of prevention have been and can aid in reducing and overcoming contagious diseases including COVID-19, still there is dearth of knowledge regarding general public awareness and perception....

Authors: Tahreem Hussain, Nida Jawed, Saba Mughal and Kashif Shafique

Citation: BMC Public Health 2022 22:528

Content type: Research Published on: 17 March 2022

Determinants of pentavalent and measles vaccination dropouts among children aged 12–23 months in The Gambia

Every year, vaccination averts about 3 million deaths from vaccine-preventable diseases (VPDs). However, despite that immunization coverage is increasing globally, many children in developing countries are sti...

Authors: Peter A. M. Ntenda, Alick Sixpence, Tisungane E. Mwenyenkulu, Kondwani Mmanga, Angeziwa C. Chirambo, Andy Bauleni and Owen Nkoka

Citation: BMC Public Health 2022 22:520

Content type: Research Published on: 17 March 2022

How (not) to mobilize health workers in the fight against vaccine hesitancy: Experimental evidence from Germany’s AstraZeneca controversy

COVID-19 vaccine hesitancy is a serious policy issue in Germany as vaccinations have stagnated at low levels compared to most other European countries. In this context, we study whether and how health workers...

Authors: Jan Priebe, Henning Silber, Christoph Beuthner and Steffen Pötztchke

Citation: BMC Public Health 2022 22:516

Content type: Research Published on: 16 March 2022

Ethical challenges and moral distress among field epidemiologists
As `disease detectives’ and directors of public health programs, field epidemiologists play essential roles in protecting public health. Although ethical issues receive considerable attention in medical and re...
Authors: Emma Cooke, George Lopez, Angela Hilmers and David G. Addiss
Citation: BMC Public Health 2022 22:510
Content type: Research Published on: 16 March 2022

**Exploring perceived risk for COVID-19 and its role in protective behavior and COVID-19 vaccine hesitancy: a qualitative study after the first wave**
The novel coronavirus pandemic (COVID-19) has had severe impacts on morbidity and mortality globally.
Authors: Naomi J. Patterson, Valerie A. Paz-Soldan, Richard Oberhelman, Lina Moses, Aubrey Madkour and Thomas T. Miles
Citation: BMC Public Health 2022 22:503

**BMC Research Notes**
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 19 Mar 2022)
[No new digest content identified]

**BMJ Evidence-Based Medicine**
February 2022 - Volume 27 - 1
https://ebm.bmj.com/content/27/1
[Reviewed earlier]

**BMJ Open**
March 2022 - Volume 12 - 3
https://bmjopen.bmj.com/content/12/3
[Reviewed earlier]

**Bulletin of the World Health Organization**
Volume 100(2); 2022 Feb 1
https://www.ncbi.nlm.nih.gov/pmc/issues/399608/
[Reviewed earlier]

**Cell**
Mar 17, 2022 Volume 18 5 Issues 6  p939-1104
https://www.cell.com/cell/current
*Articles*
**Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination**
Katharina Röltgen, et al
*Open Access*
Human antibody responses to SARS-CoV-2 differ between vaccination and infection, with mRNA vaccination inducing more productive lymph node GC responses and several vaccine types stimulating IgG antibodies capable of recognizing a broader range of viral variants.

**Child Care, Health and Development**
Volume 48, Issue 2, Pages: 177-357  March 2022
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**
Volume 111, Issue 3  Pages: 519-704  March 2022
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]

**Clinical Therapeutics**
January 2022  Volume 44  Issue 1  p1-154
http://www.clinicaltherapeutics.com/current

*Original Research*

**Willingness to Accept Expedited COVID-19 Vaccine Research for Children Aged <12 Years After Adult Vaccine Approval**

Ran D. Goldman, Jeffrey N. Bone, Renana Gelernter,... Mark A. Griffiths, Ahmed Mater, for the International COVIPAS (COVID-19 Parental Attitude Study) Group

Published online: November 15, 2021

**ABSTRACT**

**Purpose**
The goal of this study was to assess if caregivers’ attitudes toward the regulatory process of approving the vaccine against coronavirus disease 2019 (COVID-19) for children aged <12 years changed after a vaccine was approved for adults.

**Methods**
This was a larger scale COVIPAS (COVID-19 Parental Attitude Study) survey of caregivers presenting with their children aged ≤12 years for emergency care in 12 hospitals in the United States, Canada, and Israel. The study compared willingness to support abridged research into COVID-19 vaccines for children between the peak of the pandemic (March–May 2020) and after a COVID-19 vaccine became available for adults (December 2020–March 2021).

**Findings**
A total of 1956 surveys were included in the analyses. Overall, 385 (30.9%) caregivers in the pre-vaccine approval period and 250 (35.3%) caregivers in the post–adult vaccine phase supported abridged research into COVID-19 vaccines (P < 0.001). In both phases, mothers were less likely to favor abridged approval. Those with children who were fully vaccinated based on the pediatric schedule in their country favored abridged approval in phase 1 (odds ratio, 1.98; 95% confidence interval, 1.31–3.08) but less so in phase 2. In both phases, age and concerns of parents that they had COVID-19 or their child had COVID-19 were not associated with changes in response between phases.

**Implications**
Willingness to expedite vaccine approval increased after the emergency approval of COVID-19 vaccine for adults. Mothers are much less likely to approve expedited approval. No significant changes have been found in the composition of caregivers willing to forego regulatory demands on vaccine approval.

Reviews

**Dynamic Regulatory Assessment: evolving the European Regulatory Framework for the Benefit of Patients and Public Health—an EFPIA View**

Esteban Herrero-Martinez, Nasir Hussain, Nadege Le Roux,...Mark Mayer, Rodrigo Palacios, Thomas C. Kühler

Published online: November 27, 2021

p132-138

*Open Access*

**ABSTRACT**

The European Union regulatory framework supports development, review, authorization, and maintenance of medicines to benefit public health; however, many elements are 2 decades old and undergoing review. Scrutiny was triggered by the coronavirus disease 2019 pandemic, the need to support future innovative medicines, the digital transformation of data exchange, and the need to address efficiency and capacity limitations. There are also ongoing evolutions in regulatory science for medicines (eg, cell and gene therapies), medical device combinations, and software, as well as the need to fully leverage contemporary information technology (IT). Important initiatives to address these challenges include the European Medicines Agency (EMA) Regulatory Science Strategy, 1 the EU Regulatory Network Strategy,2 and the Big Data Steering Group,3 alongside European Commission–led initiatives such as the Pharmaceutical Strategy.4

Dynamic regulatory assessment (DRA) is a concept that seeks to integrate these various elements to re-imagine regulatory review interactions across the product life cycle. DRA calls for iterative regulatory dialogue, data submission, and evidence assessment, enabled by contemporary IT. DRA will facilitate iterative interaction and data assessment as it accumulates over a product’s life cycle, bringing significant efficiencies for all product types. The DRA concept primarily evolved through dialogue within working groups of the European Federation of Pharmaceutical Industries and Associations. This article describes the long-term vision of the European Federation of Pharmaceutical Industries and Associations and outlines important strategic elements of progress, including: aligning on a multi-stakeholder vision for DRA in the European Union and across regions; leveraging learnings from ongoing initiatives; and advancing IT, governance, and standards considerations. Ultimately, DRA should consider outcomes that deliver optimal benefits for patients in the European Union and worldwide.

**Clinical Trials**

Volume 19 Issue 1, February 2022

[Reviewed earlier]

**Conflict and Health**

[Accessed 19 Mar 2022]

[No new digest content identified]
Contemporary Clinical Trials
Volume 113  February 2022
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/113/suppl/C
[Reviewed earlier]

The CRISPR Journal
Volume 5, Issue 1 / February 2022
https://www.liebertpub.com/toc/crispr/5/1
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
April 2022 - Volume 35 - Issue 2
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 1  Pages: 1-62  March 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 1, 2021
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 15 - Issue 6 - December 2021
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]
Disasters
Volume 46, Issue 2  Pages: 299-586  April 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23  Issue 2  3 February 2022
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 28, Number 2—February 2022
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 38  March 2022
[Reviewed earlier]

Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 44, Issue 2  Pages: 1-40  March–April 2022
https://onlinelibrary.wiley.com/toc/25782363/current
Consent and decisional capacity; Outside experts and IRBs; Therapeutic misconception
[Reviewed earlier]

Ethics & International Affairs
Winter 2021 (35.4)  |  December 2021
https://www.ethicsandinternationalaffairs.org/2021/winter-2021-35-4/
TABLE OF CONTENTS
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 20  February 2022
The European Journal of Public Health
Volume 32, Issue 1, February 2022
https://academic.oup.com/eurpub/issue/32/1
[Reviewed earlier]

Expert Review of Vaccines
Vol 21 (1) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 1
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 19 Mar 2022]
[No new digest content identified]

Global Health Action
Volume 15, Issue 1 (2022)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
Vol. 10, No. 1 February 28, 2022
http://www.ghspjournal.org/content/current
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 19 Mar 2022]
[No new digest content identified]

Global Public Health

On February 23, 2022, the European Commission published a proposal for a Directive on Corporate Sustainability Due Diligence. The directive would lay down rules for companies with regard to actual and potential adverse human rights and environmental impacts on their own and their subsidiaries’ operations and within their value chains, as well as establish rules ... Continue reading “European Union: Commission Proposes Directive to...

Contributor: Gesley, Jenny
Date: 2022-03-15

Ensuring the global COVID-19 vaccine equity: Universal vaccine access strategy in the context of low and-middle-income countries

Ateeb Ahmad Parray, Uday Narayan Yadav, Anupom Das, ARM Mehrab Ali, Shemana Mollick, Senjuti Saha & Sabuj Kanti Mistry
Pages: 614-621
Published online: 20 Jan 2022

Unresolved COVID Controversies: ‘Normal science’ and potential non-scientific influences

Carlos F. Cáceres
Pages: 622-640
Published online: 15 Feb 2022

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 19 Mar 2022]
[No new digest content identified]

Health and Human Rights
Volume 23, Issue 2, December 2021
https://www.hhrjournal.org/volume-23-issue-2-december-2021/
[Reviewed earlier]

Health Economics, Policy and Law
Volume 17 - Issue 2 - April 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 37, Issue 3, March 2022
Possibility of COVID-19 eradication with evolution of a new omicron variant

COVID-19 has been a global health concern since 2019 until date. Global concerted efforts to combat this pandemic has resulted in a number of vaccines distributed across the globe. Although the presence of the...

Authors: Moses Okpeku
Original Investigation

**Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance**

Amadea Britton, MD; Katherine E. Fleming-Dutra, MD; Nong Shang, PhD; et al.

free access has active quiz


This study estimates the associations between symptomatic SARS-CoV-2 infection and receipt of BNT162b2, mRNA-1273, and Ad26.COVID.2 by day since vaccination before and during Delta variant predominance.
Research Letter

**Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19**
Jennifer L. Alejo, MD; Jonathan Mitchell, MBBS; Amy Chang, MD; et al.
free access has active quiz
This study uses serologic testing to characterize natural immunity and the long-term durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19 infection.

**Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection**
Lydia L. Shook, MD; Caroline G. Atyeo, BS; Lael M. Yonker, MD; et al.
free access has active quiz
This study compares the persistence of anti-spike IgG titers in infants of vaccinated mothers vs mothers who had been naturally infected with COVID-19.

**Viewpoint**

**Navigating Clinical and Business Ethics While Sharing Patient Data**
Kelly N. Michelson, MD, MPH; James G. Adams, MD; Joshua M. M. Faber, BA
free access
This Viewpoint discusses the gap between clinical medical ethics and some business practices related to patient data sharing and secondary use of data by corporations.

**JAMA Network**

**COVID-19 Update  March 19, 2022**
These articles on COVID-19 were published across the JAMA Network in the last week.

**JAMA Pediatrics**
March 2022, Vol 176, No. 3, Pages 220-332
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

**JBI Evidence Synthesis**
March 2022 - Volume 20 - Issue 3
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No digest content identified]

**Journal of Adolescent Health**
March 2022 Volume 7 0Issue 3 p351-516
https://www.jahonline.org/current
[Reviewed earlier]
Journal of Artificial Intelligence Research  
Vol. 73 (2022)  
https://www.jair.org/index.php/jair  
[Reviewed earlier]

Journal of Community Health  
Volume 47, issue 1, February 2022  
https://link.springer.com/journal/10900/volumes-and-issues/47-1  
[Reviewed earlier]

Journal of Development Economics  
Volume 155  March 2022  
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics  
Volume 17 Issue 1-2, February-April 2022  
http://journals.sagepub.com/toc/jre/current  
[Reviewed earlier]

Journal of Epidemiology & Community Health  
March 2022 - Volume 76 - 3  
https://jech.bmj.com/content/76/3  
[Reviewed earlier]

Journal of Evidence-Based Medicine  
Volume 14, Issue 4  Pages: 257-345  December 2021  
https://onlinelibrary.wiley.com/toc/17565391/current  
[Reviewed earlier]

Journal of Global Ethics  
Volume 17, Issue 3, 2021  
http://www.tandfonline.com/toc/rjge20/current  
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)  
Volume 33, Number 1, February 2022  
https://muse.jhu.edu/issue/47329  
Table of Contents  
[Reviewed earlier]
The Lancet
Mar 19, 2022 Volume 399 Number 10330 p1093-1200, e15-e16
https://www.thelancet.com/journals/lancet/issue/current

Editorial
**Nigeria: rightly taking its place on the world stage**
The Lancet

Nigeria is emerging as a world power. It has great intellectual, cultural, and social capital, as well as financial assets. It dominates west Africa, having more than half of the region's population, and has the highest gross domestic product on the continent. The population of more than 200 million is projected to double by 2050, and to reach 733 million by 2100—making Nigeria the third most populous country in the world, after China and India. This rapid population growth has been accelerated by falling infant mortality combined with a steady birth rate and can create a demographic dividend for Nigeria. But to take advantage of this situation, appropriate investments in health, education, and skills need to be made. Published today, The Lancet Nigeria Commission: investing in health and the future of the nation, views this human potential and extraordinary opportunity through a health lens, telling the story of Nigeria as shaped by the country's history and present circumstances. Written by a team of
experts working at institutions across the country, and members of the diaspora, it has been led by Nigerians for Nigerians.

This potential might not be realised if the country does not address intractable poverty and extreme inequality. Recent trends in health outcomes, as detailed in the accompanying Article published today, record 20 years of increased healthy life expectancy (although it is still low within the region, at 56 years), reductions in mortality for males and females of all ages, and rises in health expenditure but, overall, health outcomes are still poor. Nigeria has repeatedly failed to realise the health gains promised by multiple political leaders, and this failure is holding the country back...

**Articles**

**Population health outcomes in Nigeria compared with other west African countries, 1998–2019: a systematic analysis for the Global Burden of Disease Study**
Blake Angell, at al
Open Access

**Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study**
Linda-Gail Bekker, et al. the Sisonke Protocol Team, on behalf of the Sisonke Study Team

**The Lancet Commissions**

**The Lancet Nigeria Commission: investing in health and the future of the nation**
Ibrahim Abubakar, et al.
Open Access

**The Lancet Child & Adolescent Health**
Mar 2022 Volume 6 Number 3 p137-214, e6-e12
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

**Lancet Digital Health**
Mar 2022 Volume 4 Number 3 e149-e206
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

**Lancet Global Health**
Mar 2022 Volume 10 Number 3 e298-e447
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

**Lancet Infectious Diseases**
Mar 2022 Volume 22 Number 3 p297-426, e66-e100
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]
Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron

Current vaccines induce broadly cross-reactive cellular immunity against SARS-CoV-2 variants, including Omicron, and provide protection against severe disease despite a substantially reduced neutralizing antibody response.

Jinyan Liu, Abishek Chandrashekar, Dan H. Barouch

Contractual solutions to overcome drug scarcity during pandemics and epidemics

Nature Biotechnology

Volume 40 Issue 3, March 2022
https://www.nature.com/nbt/volumes/40/issues/3
Patents | 16 March 2022

Contractual solutions to overcome drug scarcity during pandemics and epidemics
Licensing provisions that obligate recipients of government funding to share relevant technology and know-how for scarce drugs during pandemics and epidemics can reduce shortages and overcome obstacles that intellectual property rights present.

Sapna Kumar
Ana Santos Rutschman

Article | 18 August 2021

Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children

Single-cell sequencing reveals pre-activated immunity as important for milder COVID-19 symptoms in children.

J. Loske, J. Röhmel, I. Lehmann

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 19 Mar 2022)
[No new digest content identified]

Nature Genetics
Volume 54 Issue 3, March 2022
https://www.nature.com/ng/volumes/54/issues/3

Editorial | 14 March 2022

Rare diseases, common challenges

The genetics community has a particularly important part to play in accelerating rare disease research and contributing to improving diagnosis and treatment. Innovations in sequencing technology and machine learning approaches have positively affected diagnostic success, but more coordinated efforts are needed to move towards effective therapies or even cures for these important, and sometimes overlooked, class of diseases.

Comment | 07 March 2022

A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United States

To build a more efficient, equitable and sustainable approach to rare disease research in the United States, we must prioritize integrated research infrastructure and approaches that focus on understanding connections across rare diseases.

Meghan C. Halley, Hadley Stevens Smith, Holly K. Tabor

Nature Human Behaviour
Volume 6 Issue 2, February 2022
https://www.nature.com/nathumbehav/volumes/6/issues/2

Focus on vaccine inequity

Equitable distribution of resources to fight COVID-19 is a global challenge. In a collection of research and opinion articles, researchers, public health officials, intellectual property experts, leaders of international organizations, and activists explain how global inequities in COVID-19 vaccine allocation continue fuelling the pandemic, and discuss ways to address these disparities.
Nature Medicine
Volume 28 Issue 2, February 2022
https://www.nature.com/nm/volumes/28/issues/2
[Reviewed earlier]

Nature Reviews Genetics
Volume 23 Issue 3, March 2022
https://www.nature.com/nrg/volumes/23/issues/3
[Reviewed earlier]

Nature Reviews Immunology
Volume 22 Issue 3, March 2022
https://www.nature.com/nri/volumes/22/issues/3
[Reviewed earlier]

Nature Reviews Drug Discovery
Volume 21 Issue 3, March 2022
https://www.nature.com/nrd/volumes/21/issues/3
Comment | 28 January 2022
A call to action for translational sciences in COVID-19 and future pandemics
Translation Together, a transnational consortium of translational research organizations, reflects on successes and challenges in regional COVID-19 pandemic responses and proposes five priorities to improve preparedness for future global public health crises and improve the global approach to translational research and science.
Kanny K. Wan, Danielle Davis, Christine M. Cutillo

New England Journal of Medicine
March 17, 2022 Vol. 386 No. 11
https://www.nejm.org/toc/nejm/medical-journal
Perspective
A Malaria Vaccine for Africa — An Important Step in a Century-Long Quest
P.L. Alonso and K.L. O'Brien
Malaria continues to devastate people’s health and livelihoods worldwide. In October 2021, the WHO for the first time recommended the large-scale use of a malaria vaccine for children living in areas with moderate-to-high malaria transmission.

Original Articles
Homologous and Heterologous Covid-19 Booster Vaccinations
R.L. Atmar and Others

Editorials
Audio Interview: Can We Make More Effective Covid-19 Vaccines?
E.J. Rubin, L.R. Baden, and S. Morrissey

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 19 Mar 2022]
[No new digest content identified]

Pediatrics
Volume 149, Issue 3, March 1, 2022
https://pediatrics.aappublications.org/
[Reviewed earlier]

PharmacoEconomics
Volume 40, issue 3, March 2022
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 19 Mar 2022)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 19 Mar 2022)
[No new digest content identified]

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 19 Mar 2022)
[No new digest content identified]

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 19 Mar 2022)
[No new digest content identified]

PLoS One
http://www.plosone.org/
Use of oral polio vaccine and the incidence of COVID-19 in the world
Farrokh Habibzadeh, Konstantin Chumakov, Mohammad M. Sajadi, Mahboobeh Yadollahie, Kristen Stafford, Ashraf Simi, Shyamasundaran Kottilil, Iman Hafizi-Rastani, Robert C. Gallo
Research Article | published 17 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0265562

The Vaccination Concerns in COVID-19 Scale (VaCCS): Development and validation
Kyra Hamilton, Martin S. Hagger
Research Article | published 14 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0264784

In seeking to understand how to protect the public information sphere from corruption, researchers understandably focus on dysfunction. However, parts of the public information ecosystem function very well, and understanding this as well will help in ...
Diana Hicks, Matteo Zullo, [....] Omar I. Asensio

Due to the enormous economic, health, and social costs of the COVID-19 pandemic, there are high expected social returns to investing in parallel in multiple approaches to accelerating vaccination. We argue there are high expected social returns to ...
Witold Więcek, Amrita Ahuja, [....] Brandon Joel Tan
Special Issue: Uncertainty in Risk Analysis: Bridging Science, Management and Communication
[New issue; No digest content identified]

Risk Management and Healthcare Policy
[Accessed 19 Mar 2022]
[No new digest content identified]

Science Translational Medicine
Volume 14| Issue 636| 16 Mar 2022
https://www.science.org/toc/stm/current
[New issue; No digest content identified]

Social Science & Medicine
Volume 292 | January 2022
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 19 Mar 2022]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 42, issue 3-4, August 2021
Special Issue: A plea for an experimental philosophy of medicine
[Reviewed earlier]
Travel Medicine and Infectious Diseases
Volume 46  March–April 2022
Review article  Full text access
Travel vaccines throughout history
Androula Pavli, Helena C. Maltezou
Article 102278

Research article  Open access
Health and security risks of humanitarian aid workers during field missions: Experience of the International Red Cross
S.C. Guisolan, M. Ambrogi, A. Meeussen, F. Althaus, G. Eperon
Article 102275

Tropical Medicine & International Health
Volume 27, Issue 3  Pages: i-iv, 217-336  March 2022
https://onlinelibrary.wiley.com/toc/13653156/current
RESEARCH ARTICLES
[Reviewed earlier]

Vaccine
Volume 40, Issue 9  Pages 1191-1384 (23 February 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/9
Short communication  Open access
Conditionality of COVID-19 vaccine acceptance in European countries
Leonardo W. Heyerdahl, Muriel Vray, Benedetta Lana, Nastassia Tvardik, ... Tamara Giles-Vernick
Pages 1191-1197

Review article  Open access
How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation
Mic McGoldrick, Thierry Gastineau, Diane Wilkinson, Cristiano Campa, ... Samir Desai
Pages 1215-1222

Review article  Open access
How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation
Mic McGoldrick, Thierry Gastineau, Diane Wilkinson, Cristiano Campa, ... Samir Desai
Pages 1223-1230

Research article  Full text access
COVID-19 vaccination intention and behavior in a large, diverse, U.S. refugee population
Jana Shaw, Kathryn B. Anderson, Rachel E. Fabi, Carlie A. Thompson, ... Andrea V. Shaw  
Pages 1231-1237

Research article  Open access  
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452  
Yester F. Janssen, Eline A. Feitsma, Hendriks H. Boersma, David G. Alleva, ... Todd C. Zion  
Pages 1253-1260

Research article  Abstract only  
Critical success factors for conducting human challenge trials for vaccine development in low- and middle-income countries  
Keiko Pempho Msusa, Taryn Rogalski-Salter, Henshaw Mandi, Ralf Clemens  
Pages 1261-1270

Research article  Open access  
Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis  
Frank G. Sandmann, Edwin van Leeuwen, Sibylle Bernard-Stoecklin, Itziar Casado, ... Marc Baguelin  
Pages 1306-1315

Research article  Abstract only  
Pertussis burden and acellular pertussis vaccine effectiveness in high risk children  
Sarah Sheridan, Peter McIntyre, Bette Liu, Parveen Fathima, ... Heather Gidding  
Pages 1376-1382

Value in Health  
March 2022 Volume 25 Issue 3 p321-472  
https://www.valueinhealthjournal.com/current  
[Reviewed earlier]

Pre-Print Servers

Gates Open Research  
https://gatesopenresearch.org/browse/articles  
[Accessed 19 Mar 2022]  
[No new digest content identified]

medRxiv  
https://www.medrxiv.org/content/about-medrxiv  
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice
or health-related behavior and should not be reported in news media as established information.

medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

**Omicron Spread in Vaccinated Jurisdictions: a Statistical Study**
Serge Dolgikh
medRxiv 2022.03.15.22272430; doi: https://doi.org/10.1101/2022.03.15.22272430

**Modelling the impact of non-pharmaceutical interventions on workplace transmission of SARS-CoV-2 in the home-delivery sector**
Carl A Whitfield, Martie Van Tongeren, Yang Han, Hua Wei, Sarah A Daniels, Martyn Regan, David W Denning, Arpana Verma, Lorenzo Pellis, University of Manchester COVID-19 Modelling Group, Ian Hall
medRxiv 2022.03.17.22272414; doi: https://doi.org/10.1101/2022.03.17.22272414

**Monoclonal antibody and antiviral therapy for treatment of mild-to-moderate COVID-19 in pediatric patients**
Surabhi B Vora, Janet A Englund, Indi Trehan, Alpana Waghmare, Ada Kong, Amanda Adler, Danielle M Zerr
medRxiv 2022.03.16.22272511; doi: https://doi.org/10.1101/2022.03.16.22272511

**Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar**
medRxiv 2022.03.17.22272529; doi: https://doi.org/10.1101/2022.03.17.22272529

**Effectiveness of whole virus COVID-19 vaccine at protecting health care personnel against SARS-CoV-2 infections in Lima, Peru**
Carmen Arriola, Giselle Soto, Matthew Westercamp, Susan Bollinger, Angelica Espinoza, Max Grogl, Alejandro Llanos-Cuentas, Eduardo Matos, Candice Romero, Maria Silva, Rachel Smith, Natalie Olson, Michael Prouty, Eduardo Aziz-Baumgartner, Fernanda Lessa
medRxiv 2022.03.16.22271100; doi: https://doi.org/10.1101/2022.03.16.22271100

**Duration of vaccine effectiveness against SARS-CoV2 infection, hospitalisation, and death in residents and staff of Long-Term Care Facilities (VIVALDI): a prospective cohort study, England, Dec 2020-Dec 2021**
Madhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, Borscha Azmi, Tom Palmer, Rebecca Giddings, Chris Fuller, Aidan Irwin-Singer, Verity Baynton, Gokhan Tut, Paul Moss, Andrew Hayward, Andrew Copas, Laura Shallcross
medRxiv 2022.03.09.22272098; doi: https://doi.org/10.1101/2022.03.09.22272098

**Acceptance of COVID 19 vaccine among sub-Saharan African (SSA): a comparative study of residents and diaspora dwellers**
Chundung Asabe Miner, Chikasirimobi G Timothy, Khathutshelo P Mashige, Uchechukwu L. Osaugwu, Esther Awazzi Enmuladu, Onyekachukwu Mary-Anne Amiebenomo, Godwin Oversoni-Ogbomo, Deborah
Examining Drivers of COVID-19 Vaccine Hesitancy in Ghana: The Roles of Political Allegiance, Misinformation Beliefs, and Sociodemographic Factors
Ken Brackstone, Kirchuffs Atengble, Michael G Head, Laud A Boateng
medRxiv 2022.03.16.22272463; doi: https://doi.org/10.1101/2022.03.16.22272463

The potential impact of Omicron and future variants of concern on SARS-CoV-2 transmission dynamics and public health burden: a modelling study
Epke A Le Rutte, Andrew J Shattock, Nakul Chitnis, Sherrie L Kelly, Melissa A Penny

Impact of COVID-19 on Life Expectancy among Native Americans
Noreen Goldman, Theresa Andrasfay
medRxiv 2022.03.15.22272448; doi: https://doi.org/10.1101/2022.03.15.22272448

COVID-19 Vaccine Hesitancy among Marginalized Populations in the U.S. and Canada: Protocol for a Scoping Review
Peter A. Newman, Luke Reid, Suchon Tepjan, Sophia Fantus, Kate Allan, Thabani Nyoni, Adrian Guta, Charmaine C. Williams
medRxiv 2022.03.15.22272438; doi: https://doi.org/10.1101/2022.03.15.22272438

The impact of COVID-19 on pregnant and recently pregnant women in Malawi: A national facility-based cohort
Chikondi Chapuma, Leonard Mndala, Luis Gadama, Fannie Kachale, Andrew Likaka, Rosemary Bilesi, Malangizo Mbewe, Bertha Maseko, Chifundo Ndamala, Regina Makuluni, Annie Kuyeri, Laura Munthali, Deborah A. Phiri, Clemens Masesa, Marc Y.R Henrion, Moses Kumwenda, David Lissauer
medRxiv 2022.03.15.22272348; doi: https://doi.org/10.1101/2022.03.15.22272348

Wellcome Open Research [to 19 Mar 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 19 Mar 2022]
Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Open Letter metrics
Revised
Maintaining laboratory quality assurance and safety in a pandemic: Experiences from the KEMRI-Wellcome Trust Research Programme laboratory’s COVID-19 response [version 2; peer review: 1 approved, 1 approved with reservations]
Peer Reviewers Talkmore Maruta; Angela Amayo

Funders
Wellcome Trust
Wellcome Trust Intermediate Fellowship
European and Developing Countries Clinical Trials Partnership (EDCTP)
International Drug Purchasing Facility
Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)
African Academy of Sciences DELTAS Africa Initiative
Program for Appropriate Technology in Health (PATH)

LATEST VERSION PUBLISHED 16 Mar 2022

* Study Protocol metrics AWAITING PEER REVIEW

A protocol for a systematic review and meta-analysis of strategies to quantify or eliminate catastrophic costs due to tuberculosis [version 1; peer review: awaiting peer review]
Paula P. Carballo-Jimenez, Sumona Datta, Rubén Aguirre-Ipenza, Matthew J. Saunders, Luz Quevedo Cruz, Carlton A. Evans
Peer Reviewers Invited
Funders
Wellcome Trust
IFHAD: Innovation For Health And Development
Joint Global Health Trials Scheme funding from the Wellcome Trust, UK Foreign, Commonwealth and Development Office, the UK Medical Research Council, and the UK Department of Health and Social Care through the National Institute of Health Research
Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica
United Kingdom Research and Innovation Quality-Related Strategic Priorities Fund

PUBLISHED 15 Mar 2022

* * * * *

Think Tanks
Brookings
http://www.brookings.edu/
Accessed 19 Mar 2022
[No new digest content identified]

Center for Global Development [to 19 Mar 2022]
https://www.cgdev.org/
Publications [Selected]
March 15, 2022
Learning Loss and Student Dropouts during the COVID-19 Pandemic: A Review of the Evidence Two Years after Schools Shut Down

Following the outbreak and spread of COVID-19 in 2020, schools around the world closed for significant periods of time. Many scholars provided projections of the likely impacts on educational outcomes, with potentially dire impacts on learning loss and—especially in low-income contexts—dropout rates. Now, two years after schools began shutting down, we identify 40 empirical studies directly estimating student learning loss (29 studies) or dropout rates (15 studies) for students in pre-primary, primary, or secondary school in countries at any income level.

Laura Moscoviz and David Evans

Chatham House  [to 19 Mar 2022]
https://www.chathamhouse.org/
Accessed 19 Mar 2022
[No new digest content identified]

CSIS
https://www.csis.org/
Accessed 19 Mar 2022
Podcast Episode
Live From Munich: Dr. Richard Hatchett “Pandemic Preparedness Needs to Be Viewed as a Security Challenge”
March 15, 2022 | By J. Stephen Morrison

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 19 Mar 2022
March 16, 2022 News Release
States Are Planning for the End of the Continuous Enrollment Requirement in Medicaid After the COVID-19 Public Health Emergency Expires, But Many Have Not Made Key Decisions
As states plan for the end of the COVID-19 public health emergency, the resumption of eligibility redeterminations and disenrollments when the continuous Medicaid enrollment requirement is lifted could lead to coverage disruptions and losses, according to a new KFF 50-state survey. The requirement, a condition of states receiving enhanced federal...

March 15, 2022 News Release
Telehealth Continues to Account for More Than a Third of Outpatient Visits for Mental Health and Substance Use Services Well into the COVID-19 Pandemic
A new analysis from KFF and Epic Research finds that telehealth visits for outpatient mental health and substance use services went from virtually zero percent in 2019 prior to the COVID-19 pandemic to a peak of 40% in mid-2020 — and continued to account for more than a third (36%)...

Rand  [to 19 Mar 2022]
China is enduring its first big outbreak of the Omicron variant. At least 40m people are under some form of lockdown (though the authorities in some regions prefer the term “life on pause”). The restrictions pose a threat to China’s economic rebound and the world’s supply chains.

In Hong Kong the death rate from covid-19 is twice as large as the peak of Britain’s second wave in early 2021. Morgues are overflowing with victims and hospitals are struggling to cope.

The latest outbreak has delayed any relaxation of China’s zero-covid policy. Our Chaquan column explains why beating covid on the mainland will require less fear, and more vaccinations.

African countries are also struggling to get people jabbed against covid. Just 13% of the continent has been fully vaccinated. Africa has plenty of covid doses but the increased deliveries are exposing logistical defects in the distribution of vaccines.

To end on a sliver of good news: covid has led to other vaccine victories. Our data-driven coverage this week shows how a jab against malaria is arriving at last. It could save as many lives as covid has taken. And in our Asia section, we look at changing attitudes towards the human papillomavirus vaccine in Japan as inoculations become more routine.
Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *
* * * *